Accéder au contenu
Merck

FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice.

Cell metabolism (2018-05-01)
Xuebo Pan, Yihui Shao, Fan Wu, Yuan Wang, Rongrong Xiong, Jujia Zheng, Haishan Tian, Baile Wang, Yanfang Wang, Yi Zhang, Zongsheng Han, Aijuan Qu, Haixia Xu, Aihua Lu, Tianxin Yang, Xiaokun Li, Aimin Xu, Jie Du, Zhuofeng Lin
RÉSUMÉ

Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage. In addition, ACE2 deficiency strikingly abrogates these beneficial effects of FGF21 in mice, including alleviation of angiotensin II-associated hypertension and vascular damage. Otherwise, pharmaceutical inhibition of angiotensin-(1-7) attenuates the protective effect of FGF21 on angiotensin II-induced vascular dysfunction, but not on hypertension. Thus, FGF21 protects against angiotensin II-induced hypertension and vascular impairment by activation of the ACE2/angiotensin-(1-7) axis via fine-tuning the multi-organ crosstalk between liver, adipose tissue, kidney, and blood vessels.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Angiotensine II humaine, ≥93% (HPLC), powder
Sigma-Aldrich
Désoxyribonucléase I from bovine pancreas, Type II, lyophilized powder, Protein ≥80 %, ≥2,000 units/mg protein